{"id":"https://openalex.org/W166785877","doi":null,"title":"The clinical pharmacology of ribavirin.","display_name":"The clinical pharmacology of ribavirin.","publication_year":1999,"publication_date":"1999-01-01","ids":{"openalex":"https://openalex.org/W166785877","mag":"166785877","pmid":"https://pubmed.ncbi.nlm.nih.gov/10349689"},"language":"en","primary_location":{"id":"pmid:10349689","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10349689","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Seminars in liver disease","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5022110262","display_name":"Paul Glue","orcid":"https://orcid.org/0000-0002-7305-2800","observed_orcids":["https://orcid.org/0000-0002-7305-2800"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"P Glue","raw_affiliation_strings":["Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5022110262"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.6414,"has_fulltext":false,"cited_by_count":217,"citation_normalized_percentile":{"value":0.94822965,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"19 Suppl 1","issue":null,"first_page":"17","last_page":"24"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.38769999146461487,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.38769999146461487,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.3617999851703644,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.03240000084042549,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ribavirin","display_name":"ribavirin","score":1.0},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9909999966621399},{"id":"https://openalex.org/keywords/oral-absorption","display_name":"oral absorption","score":0.6899999976158142},{"id":"https://openalex.org/keywords/bioavailability","display_name":"bioavailability","score":0.7490000128746033},{"id":"https://openalex.org/keywords/volume-of-distribution","display_name":"volume of distribution","score":0.8349999785423279},{"id":"https://openalex.org/keywords/plasma-protein-binding","display_name":"plasma protein binding","score":0.7940000295639038},{"id":"https://openalex.org/keywords/elimination-half-life","display_name":"elimination half-life","score":0.8180000185966492},{"id":"https://openalex.org/keywords/food-effect","display_name":"food effect","score":0.6899999976158142},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.8889999985694885},{"id":"https://openalex.org/keywords/antiviral-agents","display_name":"antiviral agents","score":0.6349999904632568}],"concepts":[{"id":"https://openalex.org/C2780040827","wikidata":"https://www.wikidata.org/wiki/Q421862","display_name":"Ribavirin","level":4,"score":0.9722068309783936},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8243786692619324},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.7021033763885498},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5986405611038208},{"id":"https://openalex.org/C139254425","wikidata":"https://www.wikidata.org/wiki/Q1332167","display_name":"Volume of distribution","level":3,"score":0.5381262302398682},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5364492535591125},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.48387038707733154},{"id":"https://openalex.org/C2776543447","wikidata":"https://www.wikidata.org/wiki/Q28734","display_name":"Nucleoside","level":2,"score":0.44998878240585327},{"id":"https://openalex.org/C110121322","wikidata":"https://www.wikidata.org/wiki/Q865811","display_name":"Distribution (mathematics)","level":2,"score":0.43079525232315063},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.30645304918289185},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.14556050300598145},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C135763542","wikidata":"https://www.wikidata.org/wiki/Q106016","display_name":"Genotype","level":3,"score":0.0},{"id":"https://openalex.org/C134306372","wikidata":"https://www.wikidata.org/wiki/Q7754","display_name":"Mathematical analysis","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000042","descriptor_name":"Absorption","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077190","descriptor_name":"Interferon alpha-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001692","descriptor_name":"Biological Transport","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007421","descriptor_name":"Intestine, Small","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012254","descriptor_name":"Ribavirin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D012254","descriptor_name":"Ribavirin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:10349689","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10349689","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Seminars in liver disease","raw_type":"Journal Article"},{"id":"mag:166785877","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10349689","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2009523275","https://openalex.org/W2081060643","https://openalex.org/W2398836744","https://openalex.org/W2352672171","https://openalex.org/W1984165369","https://openalex.org/W2349200394","https://openalex.org/W2417851047","https://openalex.org/W2377229730","https://openalex.org/W2389566491","https://openalex.org/W2018432327"],"abstract_inverted_index":{"This":[0],"article":[1],"summarizes":[2],"pharmacokinetic":[3,131],"studies":[4],"of":[5,68,114,117,133,140],"ribavirin":[6,118,134,150],"in":[7,102,135],"healthy":[8],"volunteer":[9],"and":[10,31,104,145,151],"patient":[11],"populations.":[12],"Ribavirin":[13,49,88],"is":[14,41,58,70,99,107,126],"rapidly":[15],"absorbed":[16],"after":[17],"oral":[18],"administration":[19],"(time":[20],"to":[21,51,63,76,92],"maximum":[22],"concentration":[23],"=":[24],"1.5":[25],"hours),":[26],"followed":[27],"by":[28,109],"rapid":[29],"distribution":[30,69,78],"prolonged":[32],"elimination":[33,116],"phases.":[34],"Uptake":[35],"from":[36,119],"the":[37,122,138,146],"proximal":[38],"small":[39],"bowel":[40],"active":[42],"via":[43,85],"concentrative":[44],"N1":[45],"sodium-dependent":[46],"nucleoside":[47],"transporters.":[48,87],"appears":[50],"be":[52],"extensively":[53],"absorbed;":[54],"however,":[55],"absolute":[56],"bioavailability":[57],"approximately":[59,110,127],"50%,":[60],"probably":[61],"due":[62,75],"first-pass":[64],"metabolism.":[65],"Apparent":[66],"volume":[67],"extensive":[71,100],"(approximately":[72],"2,000":[73],"L)":[74],"ribavirin's":[77,143],"into":[79],"nonplasma":[80,120],"(cellular)":[81],"compartments,":[82,121],"which":[83],"occurs":[84],"es-nucleoside":[86],"does":[89],"not":[90],"bind":[91],"plasma":[93],"proteins.":[94],"Upon":[95],"multiple":[96,123],"dosing":[97],"there":[98],"accumulation":[101],"plasma,":[103],"steady":[105],"state":[106],"achieved":[108],"4":[111],"weeks.":[112],"Because":[113],"slow":[115],"dose":[124],"half-life":[125],"298":[128],"hours.":[129],"The":[130],"properties":[132],"special":[136],"populations,":[137],"effect":[139],"food":[141],"on":[142],"pharmacokinetics,":[144],"potential":[147],"interactions":[148],"between":[149],"other":[152],"agents":[153],"are":[154],"also":[155],"reviewed.":[156]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":11},{"year":2014,"cited_by_count":12},{"year":2013,"cited_by_count":12},{"year":2012,"cited_by_count":7}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}